Therapeutic Substances Regulations 1956 (Amendment)

Overview

The Therapeutic Substances Act 1953 was enacted to regulate the importation, manufacture, and sale of therapeutic substances in Australia. This legislation aims to ensure that therapeutic substances available to the public are safe, of high quality, and appropriately labelled. The Therapeutic Substances Regulations 1956, made under the authority of this Act, further detail the requirements for the packaging and labelling of controlled therapeutic substances to safeguard public health. The 1956 statutory rules, particularly those concerning the amendment of the Therapeutic Substances Regulations, illustrate a commitment to enhancing the legibility and accessibility of information on therapeutic substances, ensuring that the official name of the substances is prominently displayed in a minimum six-point type. These regulations were introduced to address the need for clear and consistent labelling to prevent misuse and ensure accurate identification of therapeutic substances by healthcare professionals and consumers.

Scope and Application

The Therapeutic Substances Act 1953, as amended by the Statutory Rules 1956, No. 113, regulates the packaging and labelling of controlled therapeutic substances within the Commonwealth of Australia. This legislation applies to entities and individuals involved in the production, importation, supply, and distribution of therapeutic substances, ensuring that these substances are accurately identified and safely managed. The amendment specifically mandates that the official name of any controlled therapeutic substance on packaging or labelling must be presented in a font size of at least six point type, ensuring clarity and compliance with regulatory standards. The scope of the Act is national, applying uniformly across all states and territories within Australia, and it extends through subordinate instruments to ensure thorough implementation and enforcement of the regulations. The Therapeutic Substances Regulations, as amended, set forth detailed requirements to maintain the integrity and safety of therapeutic substances. These regulations do not specify exclusions or exemptions but focus on the precise and uniform application of labelling standards across the therapeutic substances industry. The Act is comprehensive, covering all aspects of therapeutic substances from manufacturing to retail, ensuring that all entities involved adhere to the stipulated standards. The amendments are part of a broader legislative framework aimed at protecting public health by ensuring that therapeutic substances are accurately labelled and safely managed throughout their distribution lifecycle.

Key Provisions

The key operative sections of this Statutory Rules document amend the Therapeutic Substances Regulations under the Therapeutic Substances Act 1953. Specifically, Regulation 5 is amended to update the requirements for the packaging and labelling of controlled therapeutic substances (s. 5). The amendment focuses on the size of the lettering or symbols used to display the official name of the substance, stipulating that the size must not be less than six-point type. This change aims to ensure clarity and readability of the official names on the packaging. The obligations imposed by this regulation pertain primarily to manufacturers and distributors of controlled therapeutic substances. They must ensure that the packaging and labelling of their products comply with the new requirements set forth in Regulation 5. This includes verifying that the official names of substances are printed in a font size of at least six-point type, which is intended to enhance the visibility and legibility of these names for consumers and healthcare professionals. In the event of non-compliance with the amended Regulation 5, there may be civil or criminal consequences depending on the nature and severity of the breach. Although the document does not specify maximum penalties, violations of packaging and labelling requirements under the Therapeutic Substances Act 1953 could potentially lead to enforcement actions by regulatory authorities. These actions might include fines, product recalls, or other corrective measures to address non-compliance and ensure public safety.